GLPwatch
Saxenda vs Zepbound
Drug comparison
Last updated 2026-05-28 15:46 UTCSaxenda (liraglutide) and Zepbound (tirzepatide) are both injectable prescription medications for obesity, made by Novo Nordisk and Eli Lilly respectively. Saxenda is approved only for obesity, while Zepbound is also approved for obstructive sleep apnea. Both are given as weekly under-the-skin shots, but they contain different active ingredients.
AI summary of the sources below.
| Saxenda | Zepbound | |
|---|---|---|
| Active ingredient | liraglutide | tirzepatide |
| Manufacturer | novo-nordisk | eli-lilly |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | obesity | obesity, obstructive sleep apnea |
| Label updated | 2026-02-25 | 2026-04-22 |